PD-L1 inhibitors
1 product
11 abstracts
Abstract
Immune checkpoint inhibitor plus chemotherapy versus chemotherapy alone in HER2-negative advanced gastric or gastroesophageal junction cancer: A systematic review and meta-analysis of randomized controlled trials.Org: Federal Univerity of Rio de Janeiro, DASA Oncologia, Federal University of Ceará, Clion Clínica de Oncologia, Hospital São Domingos,
Abstract
Immunotherapy plus chemotherapy versus chemotherapy alone in perioperative treatment for locally advanced gastric cancer: A systematic review and meta-analysis.Org: Federal University of São João Del-rei, Divinópolis, Brazil, Federal Univerity of Rio de Janeiro, Rio De Janeiro, Brazil, Federal University of Ceará, Fortaleza, Brazil, DASA Oncologia, São Paulo, Brazil, Clion Clínica de Oncologia, Salvador, Brazil,
Abstract
First-line immunotherapy plus chemotherapy for ES-SCLC: Comparison between PD-1 and PD-L1 inhibitors in a real-world setting.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, Shandong Cancer Hospital, Shandong First Medical University, Jinan, China,
Abstract
Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma: A single-center real-world study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China,
Abstract
Efficacy and safety of immunotherapy in patients with liver metastases in patients with esophageal cancer: A retrospective, real-world study.Org: Luoyang Central Hospital affiliated to Zhengzhou University, Xinxiang Medical University,
Abstract
Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis of randomized controlled trials.Org: Federal University of Sao Paulo - UNIFESP,
Abstract
Effectiveness of adjuvant immunotherapy in muscle-invasive urothelial cancer: A systematic review and meta-analysis of randomized controlled trials.Org: Federal University of São João Del-rei, Divinópolis, Brazil, Divinópolis, Brazil, Brazil, Federal University of Rio Grande do Norte, Natal,
Abstract
Effect of immunotherapy combined with chemotherapy with or without thoracic radiotherapy on markers of myocardial injury in patients with thoracic tumors.Org: Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Clinical Cancer Centre, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.Org: Syneos Health, Morrisville, NC, NC Medical Research, Gurugram, Indiana University – Purdue University Indianapolis,
Abstract
Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: Incidence, pattern of failure and clinical value of local consolidative therapy.Org: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China, Shanghai, China, Gracell Biotechnologies, Ltd., Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Centre, Shanghai, China,
Abstract
Correlation analysis to assess surrogate endpoints for overall survival (OS) in triple-negative breast cancer (TNBC).Org: The Larvol Group, LLC, Labcorp Drug Development Inc., Princeton, NJ, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust,